Immune Checkpoints Inhibitors and SRS/SBRT Synergy in Metastatic Non-Small-Cell Lung Cancer and Melanoma: A Systematic Review

<span style="text-decoration: underline;"><i>Background:</i></span> Several immunotherapy (IT) agents are FDA approved for treatment of melanoma and non-small-cell lung cancer (NSCLC). The addition of stereotactic radiosurgery (SRS) or stereotactic body radiation th...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	María Rodríguez Plá, Diego Dualde Beltrán, Eduardo Ferrer Albiach
Formato:	article
Lenguaje:	EN
Publicado:	MDPI AG 2021
Materias:	stereotactic radiosurgery stereotactic body radiation therapy immune checkpoint inhibitors radiation therapy anti-PD-L1 anti-CTLA4 Biology (General) QH301-705.5 Chemistry QD1-999
Acceso en línea:	https://doaj.org/article/fe1d7f9a6ef14d4db35936f79a05f4b3
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:fe1d7f9a6ef14d4db35936f79a05f4b3
record_format	dspace
spelling	oai:doaj.org-article:fe1d7f9a6ef14d4db35936f79a05f4b32021-11-11T17:05:57ZImmune Checkpoints Inhibitors and SRS/SBRT Synergy in Metastatic Non-Small-Cell Lung Cancer and Melanoma: A Systematic Review10.3390/ijms2221116211422-00671661-6596https://doaj.org/article/fe1d7f9a6ef14d4db35936f79a05f4b32021-10-01T00:00:00Zhttps://www.mdpi.com/1422-0067/22/21/11621https://doaj.org/toc/1661-6596https://doaj.org/toc/1422-0067<span style="text-decoration: underline;"><i>Background:</i></span> Several immunotherapy (IT) agents are FDA approved for treatment of melanoma and non-small-cell lung cancer (NSCLC). The addition of stereotactic radiosurgery (SRS) or stereotactic body radiation therapy (SBRT) to immunotherapy looks promising. A systematic review was conducted to evaluate the possible synergistic effects of immune checkpoints inhibitors (ICIs) and stereotactic radiation therapy in melanoma and NSCLC. <span style="text-decoration: underline;"><i>Materials and methods:</i></span> Pubmed databases from January 2010 to December 2020 were reviewed to identify English language studies reporting control of local and abscopal effect of the combination of ICI-SBRT/SRS in metastatic NSCLC and melanoma cancer. The inclusion criteria were followed according to PICO criteria. <span style="text-decoration: underline;"><i>Results:</i></span> Thirty-nine articles were included of the 2141 initial results. The reported rates for local control were 16.5–100% and 40–94% in brain and extracerebral metastases, respectively. Distant/abscopal response rates were 1–45% in extracerebral metastases. Abscopal effect could not be evaluated in brain metastases because it was not reported in studies. Treatments were well tolerated with few grade 4 toxicities and no grade 5. <span style="text-decoration: underline;"><i>Conclusions:</i></span> The combined treatment of ICI-SBRT/SRS achieves high local control and non-negligible abscopal response in patients with extracerebral metastases, with its benefit in cerebral metastases being more controversial. Clinical trials are needed to better characterize the potential synergism.María Rodríguez PláDiego Dualde BeltránEduardo Ferrer AlbiachMDPI AGarticlestereotactic radiosurgerystereotactic body radiation therapyimmune checkpoint inhibitorsradiation therapyanti-PD-L1anti-CTLA4Biology (General)QH301-705.5ChemistryQD1-999ENInternational Journal of Molecular Sciences, Vol 22, Iss 11621, p 11621 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	stereotactic radiosurgery stereotactic body radiation therapy immune checkpoint inhibitors radiation therapy anti-PD-L1 anti-CTLA4 Biology (General) QH301-705.5 Chemistry QD1-999
spellingShingle	stereotactic radiosurgery stereotactic body radiation therapy immune checkpoint inhibitors radiation therapy anti-PD-L1 anti-CTLA4 Biology (General) QH301-705.5 Chemistry QD1-999 María Rodríguez Plá Diego Dualde Beltrán Eduardo Ferrer Albiach Immune Checkpoints Inhibitors and SRS/SBRT Synergy in Metastatic Non-Small-Cell Lung Cancer and Melanoma: A Systematic Review
description	<span style="text-decoration: underline;"><i>Background:</i></span> Several immunotherapy (IT) agents are FDA approved for treatment of melanoma and non-small-cell lung cancer (NSCLC). The addition of stereotactic radiosurgery (SRS) or stereotactic body radiation therapy (SBRT) to immunotherapy looks promising. A systematic review was conducted to evaluate the possible synergistic effects of immune checkpoints inhibitors (ICIs) and stereotactic radiation therapy in melanoma and NSCLC. <span style="text-decoration: underline;"><i>Materials and methods:</i></span> Pubmed databases from January 2010 to December 2020 were reviewed to identify English language studies reporting control of local and abscopal effect of the combination of ICI-SBRT/SRS in metastatic NSCLC and melanoma cancer. The inclusion criteria were followed according to PICO criteria. <span style="text-decoration: underline;"><i>Results:</i></span> Thirty-nine articles were included of the 2141 initial results. The reported rates for local control were 16.5–100% and 40–94% in brain and extracerebral metastases, respectively. Distant/abscopal response rates were 1–45% in extracerebral metastases. Abscopal effect could not be evaluated in brain metastases because it was not reported in studies. Treatments were well tolerated with few grade 4 toxicities and no grade 5. <span style="text-decoration: underline;"><i>Conclusions:</i></span> The combined treatment of ICI-SBRT/SRS achieves high local control and non-negligible abscopal response in patients with extracerebral metastases, with its benefit in cerebral metastases being more controversial. Clinical trials are needed to better characterize the potential synergism.
format	article
author	María Rodríguez Plá Diego Dualde Beltrán Eduardo Ferrer Albiach
author_facet	María Rodríguez Plá Diego Dualde Beltrán Eduardo Ferrer Albiach
author_sort	María Rodríguez Plá
title	Immune Checkpoints Inhibitors and SRS/SBRT Synergy in Metastatic Non-Small-Cell Lung Cancer and Melanoma: A Systematic Review
title_short	Immune Checkpoints Inhibitors and SRS/SBRT Synergy in Metastatic Non-Small-Cell Lung Cancer and Melanoma: A Systematic Review
title_full	Immune Checkpoints Inhibitors and SRS/SBRT Synergy in Metastatic Non-Small-Cell Lung Cancer and Melanoma: A Systematic Review
title_fullStr	Immune Checkpoints Inhibitors and SRS/SBRT Synergy in Metastatic Non-Small-Cell Lung Cancer and Melanoma: A Systematic Review
title_full_unstemmed	Immune Checkpoints Inhibitors and SRS/SBRT Synergy in Metastatic Non-Small-Cell Lung Cancer and Melanoma: A Systematic Review
title_sort	immune checkpoints inhibitors and srs/sbrt synergy in metastatic non-small-cell lung cancer and melanoma: a systematic review
publisher	MDPI AG
publishDate	2021
url	https://doaj.org/article/fe1d7f9a6ef14d4db35936f79a05f4b3
work_keys_str_mv	AT mariarodriguezpla immunecheckpointsinhibitorsandsrssbrtsynergyinmetastaticnonsmallcelllungcancerandmelanomaasystematicreview AT diegodualdebeltran immunecheckpointsinhibitorsandsrssbrtsynergyinmetastaticnonsmallcelllungcancerandmelanomaasystematicreview AT eduardoferreralbiach immunecheckpointsinhibitorsandsrssbrtsynergyinmetastaticnonsmallcelllungcancerandmelanomaasystematicreview
_version_	1718432217648070656

Immune Checkpoints Inhibitors and SRS/SBRT Synergy in Metastatic Non-Small-Cell Lung Cancer and Melanoma: A Systematic Review

Ejemplares similares